Skip to main content
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. — Investor Relations & Filings

Ticker · VTVT ISIN · US9183852048 LEI · 549300WQE5EI9R35SE66 US Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-05-09 Interim / Quarterly Rep…
Country US United States of America
Listing US VTVT

About vTv Therapeutics Inc.

https://vtvtherapeutics.com/

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. The company's primary commitment is to improving the lives of patients with diabetes. Its lead clinical drug candidate is cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. In collaboration with development partners, vTv is also pursuing additional indications for its pipeline molecules, including type 2 diabetes and other chronic conditions.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2024, by vTv Therapeutics Inc. It announces the issuance of a press release containing financial results for the fiscal quarter ended March 31, 2024. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a notification of the earnings release. According to the 'MENU VS MEAL' rule, such a short document announcing the release of financial results and attaching a press release is classified as an Earnings Release (ER). The document length is 3702 characters, which is short and consistent with an earnings release announcement rather than a full report. Therefore, the appropriate classification is Earnings Release (ER).
2024-05-09 English
Regulatory Filings 2024
Regulatory Filings
2024-04-30 English
424B2
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(2) related to an at-the-market offering of Class A common stock by vTv Therapeutics Inc. It includes detailed information about the offering, sales agreement, risk factors, use of proceeds, dilution, and plan of distribution. The document references the Securities Act of 1933 and the SEC, and it is part of a registration statement on Form S-3. This type of document is a capital raising disclosure, specifically a prospectus for a stock offering. It is not an annual report, earnings release, or any other type of financial report. It is a capital/financing update related to the company's fundraising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence score.
2024-04-29 English
424B2
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(2) related to a securities offering by vTv Therapeutics Inc. It describes the terms of securities to be offered, including Class A common stock, preferred stock, debt securities, warrants, rights, and units, with an aggregate offering price of up to $250 million. The document references SEC registration numbers, filing dates, and includes detailed information about the offering, risk factors, use of proceeds, and incorporation by reference of other SEC filings such as the Annual Report on Form 10-K and Current Reports on Form 8-K. The document is clearly a registration statement prospectus related to capital raising activities and financing. It is not a financial report, earnings release, management discussion, or any other type of report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence level.
2024-04-29 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and is signed by the CFO. The content is a formal request related to a registration statement effectiveness, not the registration statement itself or any financial data. The document length is short (1409 characters) and it is clearly an announcement/request letter rather than a report or filing containing financial data. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.